home / stock / nvo / nvo articles

NVO Articles, Novo Nordisk A/S - From 02/05/24

Stock Information
Company Name: Novo Nordisk A/S
Stock Symbol: NVO
Market: NYSE
Website: novonordisk.com
Menu
NVO NVO Quote NVO Short NVO News NVO Articles NVO Message Board
Get NVO Alerts

News, Short Squeeze, Breakout and More Instantly...
Ozempic Maker Strikes $11B Deal With Catalent As It Rushes To Meet Massive Weight-Loss Drug Demand | Benzinga

Maker of ‘miracle’ weight loss drugs Ozempic and Wegovy, Novo Nordisk A/S (NYSE:NVO) has announced the acquisition of three fill-finish...
Take Your Ozempic: Why Late Entry Of Rival Weight-Loss Drugs Won't Floor Novo, Eli Shares | Benzinga

Eli Lilly (NYSE:LLY) reports its fourth quarter earnings next week and, as Novo Nordisk (NYSE:NVO) did on Wednesday, is expected to wow investors w...

With Bumper $33B Sales, Novo Nordisk Forecasts Double-Digit 2024 Earnings Growth, Boosts Lower Dose Wegovy US Supplies | Benzinga

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported fourth quarter of 2023 sales of DKK 65.86 billion ($9.5 billion compared to the consensus of...

Novo Nordisk Skyrockets To $506B Valuation Driven By 'Miracle' Drugs Ozempic, Wegovy | Benzinga

Novo Nordisk (NYSE:NVO) has reported a remarkable increase in its market value, reaching $500 billion, driven by a surge in demand for its key drug...
Eli Lilly Wants to Expand Access to Weight-Loss Treatments In Germany, In Talks With Government | Benzinga

Eli Lilly And Co (NYSE:LLY) is reportedly engaged in discussions with the German government to lift the ban on the public health system coveri...

Eli Lilly's Famed Obesity And Diabetes Drug, Mounjaro, Comes To UK Patients, Wins Regulatory Clearance For Prefilled Injection Pen | Benzinga

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved, Thursday, a four-dose version of the diabetes and weight manageme...

Weight Loss Drug's Ozempic Counterfeit: Rising Reports Over Patient Safety Related Fake Drugs | Benzinga

Three individuals sought medical attention for dangerously low blood sugar in the U.S. in the previous year, having taken suspected fake versions o...
Jim Cramer Says Eli Lilly Could Replace Tesla In 'Magnificent Seven' List: 'To Ignore...Is To Reject The Facts' | Benzinga

Jim Cramer, the host of CNBC’s “Mad Money,” has hinted at the possibility of Tesla Inc (NASDAQ:TSLA) being replaced by Eli Lilly ...

European Drug Regulator To Consider Expanded Use Of Novo Nordisk's Wegovy Weight-Loss Drug | Benzinga

The European Medicines Agency (EMA) is set to discuss extending the application of Novo Nordisk A/S’s (NYSE:NVO) weight loss drug, ...

Weightloss Drugs Ozempic And Wegovy's Success Sets Novo Nordisk's Owner To Utilize Dividend Windfall For Strategic Investments | Benzinga

In a recent interview, Kasim Kutay, Chief Executive Officer of Novo Holdings, announced the company’s ambitious plans for further a...
Previous 10 Next 10